Investor relations

The main actions

The idea behind the project is to design and produce innovative medical devices for the prevention and treatment of infections, with characteristics suitable for application in multiple surgical disciplines such as, for example, Orthopedics and Traumatology, Neurosurgery, Vascular Surgery, General, Reconstructive Plastic, Oral-Maxillofacial Surgery, Urology and Gynecology.

Knowledge and Skills

The knowledge and skills acquired in years of experience in this sector by the founding partners and their collaborators are such as to allow the development of medical devices, capable of solving the most important problems or surgical complications, responding to requests for materials that simplify surgical procedures and reduce the time of hospitalization and functional recovery of patients;

Scientifically validated products

Through a policy strongly based on innovation and Education, Sterify involves affirmed Italian and foreign Opinion Leaders and forms an international professional network able to scientifically and clinically validate the new products.


Innovation and Education

Through a policy strongly based on innovation and Education, Sterify involves affirmed Italian and foreign Opinion Leaders and forms an international professional network able to scientifically and clinically validate the new products.

Strategic choice

From the regulatory point of view, it is considered strategic the choice to approach first the dental market with applications in the periodontal and peri-implant field, for two main reasons:

1) faster certification process (average time-to-market, 18-24 months) and less onerous in terms of pre-marketing investments to support the costs of biocompatibility and pre-clinical/clinical validation

2) faster return-to-investment, relying on a very large potential market and clinical follow-up of efficacy verification equal to 3 months on average, in the case of treatment of periodontitis and peri-implantitis.


€ 327.500



Current evaluation

€ 4.827.500



Company type

Innovative Startup

Project investment details

Objective 150.000€
Invested 327.500€


€ 4.827.500

Why invest?

Management credibility

The Management Team boasts decades of experience in Research, Development, Production and Distribution of Medical Devices for Regenerative Medicine. In 2017 the team founded Tiss’You Srl, developing and certifying 4 lines of tissue substitutes for the regeneration of damaged connective tissues, managing to pursue the strategic objectives of the Business Plan despite the spring 2020 lockdown.

Lean structure and reduced fixed costs

The production processes have been designed in such a way as to keep fixed costs very low, outsourcing some production phases to validated and certified partners.

Consolidated network

Sterify, thanks to the commercial relationships consolidated over time by the members of the Management Team, will immediately boast a capillary distribution network in Europe and the Middle East.a and reduced fixed costs.

Market application

For decades, the World Health Organization (WHO) has been asking public bodies and companies to invest in researching new products for the treatment and prevention of bacterial infections, since the phenomenon of antibiotic resistance has been known for a long time. By 2050 it will lead to the death of 10 million individuals. The need for investment in this sector represents one of the strategic objectives of the Global Action Plan against antimicrobial resistance approved by the 68th World Health Assembly held in Geneva in May 2015. Contrary to what the WHO requested and hoped for, the number of devices or drugs developed in recent years, compared to the previous decade, has dropped dramatically. Fewer and fewer companies are able to identify molecules or mixtures of them capable of meeting the requirements of the regulations on drugs or medical devices, making the few companies in the sector even more attractive for investments and possible future acquisitions.

Market potential

Sterify’s target market was US $ 27.1 billion in 2015 and is expected to be US $ 35.6 billion in 2022.

Dynamism and attractiveness of the sector (Exit)

several large international operators (Allergan, AstraZeneca, Roche, Gilead Sciences, Novartis etc.) have invested in recent years in acquisitions of companies in the biomedical sector, with Post-Acquisition Prices up to 30x.

Tax deductions

Sterify Srl is an innovative startup and this allows you to take advantage of the deductions to (click here for more information).

Accomplished results

Sterify S.r.l. was born in 2020 as a spin-off of Tiss’ You srl, a “Regenerative Company” that deals with Research & Development in the field of medical devices to improve the natural healing capacity of trauma. The Sterify project was started in 2018 and after following the entire process of research, validation of effectiveness and patenting, it is now ready to attack the market.

Below, in brief, the stages of the results achieved by the company: